ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Type 2 Diabetes-Associated Phenylacetylglutamine Induces Deleterious Inflammation Cycle in Myeloid Cells through β
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cardiovascular-kidney-metabolic syndrome through the lens of gut‑derived uremic toxins.Gut microbes · 2026Review
- Integrated analysis of gut microbiota, serum metabolomics, and proteomics reveals novel associations with clinical symptoms in patients with cerebral infarction.BMC microbiology · 2026Article
- Immunomodulatory hydrogel reprograms IL-17/NF-κB signaling to drive regeneration in diabetic wounds.Materials today. Bio · 2026Article
- Gut microbiota in type 2 diabetes mellitus: mechanistic links between dysbiosis, insulin resistance, and chronic low-grade inflammation.Frontiers in endocrinology · 2026Review
- Compound phellodendron decoction promotes post-fistulotomy wound healing by downregulating neutrophil extracellular traps formation: evidence from a randomized trial and mechanistic studies.Frontiers in pharmacology · 2026Article
- Metabolomics identifies chenodeoxycholic acid as a protective factor in diabetic foot ulcers.Frontiers in endocrinology · 2026Article
- Retrospective cohort study of type 2 diabetes effects on chronic wound healing in dermatology clinics.Bioinformation · 2026Article
- Type 2 Diabetes-Associated Phenylacetylglutamine Induces Deleterious Inflammation Cycle in Myeloid Cells through βAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Evolutionary diversification and expressional profile of adrenergic receptors in the Pacific oyster Crassostrea gigas.BMC genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Despite advances in glucose-lowering therapies, many diabetic patients still suffer inflammation-related complications such as chronic non-healing wounds. The microbiota-derived metabolite phenylacetylglutamine (PAGln) is identified as a causal driver of these wounds via a transmissible, β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.